Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26.50 on Endo Health Solutions on Lower Guidance

Share:
Related ENDP
RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan
Benzinga's Top Upgrades
More Pharma Buyouts Ahead? 3 Top Stocks In Buy Range (Investor's Business Daily)

Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions (NASDAQ: ENDP) but reduced its price target from $40 to $38.

Stifel Nicolaus commented, "As hoped for, Endo finally put forth what we consider realistic guidance following several over-promises in 2012 that culminated in December's guidance pull and a CEO change by May 2013. … Though guidance is lower than our already modest expectations, we favor this conservative outlook on the year, and look for potential strategic shift with the upcoming CEO change. We are reducing our estimates (2013 $4.50, 2014 trough $4.00) and lowering our target price from $40 to $38 to reflect new guidance."

Endo Health Solutions closed at $26.25 on Thursday.

Latest Ratings for ENDP

DateFirmActionFromTo
Jul 2015RBC CapitalUpgradesOutperformTop Pick
Jun 2015Stifel NicolausMaintainsBuy
Jun 2015Raymond JamesInitiates Coverage onMarket Perform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ENDP)

Get Benzinga's Newsletters